د.عبدالله علي الشرم retweeted
NEONIPIGA: CAN WE AVOID CHEMOTHERAPY AND EVEN GASTRECTOMY?
🔹 Background: MSI-H/dMMR gastric/GEJ cancers are highly sensitive to immunotherapy.
🔹 Study: Phase II NEONIPIGA evaluated neoadjuvant nivolumab + ipilimumab without chemotherapy in 32 patients with resectable disease.
🔹 Part 1: Remarkable 58.6% pathological complete response (pCR).
🔹 Part 2: At 4 years, EFS 83.5% | OS 84.1%.
🔹 The big question: Can complete responders safely avoid gastrectomy?
⚠️ Verdict: Promising, but organ preservation remains investigational.
📚 André et al. JCO 2023; Samaille et al. JAMA Oncol 2026.
#NEONIPIGA #GastricCancer #MSIH #dMMR #Immunotherapy #MVOnco
@OncoDaily @OncoAlert @larvol
د.عبدالله علي الشرم retweeted
PROTEUS: Positive trial, but are we overtreating? 🤔
An interesting NEJM debate raises important questions.
🔹 PROTEUS: MFS improved (HR 0.80; P = 0.02), with a 4.7% absolute gain at 5 years.
🔹 The controversy:
- PSMA PET-inclusive MFS: HR 0.80 (95% CI 0.67–0.95) ✅ Significant
- Conventional-imaging MFS: HR 0.84 (95% CI 0.69–1.03) ❌ Not significant
🔹 Authors' defense: Both favour treatment; fewer conventional-imaging events limit statistical power.
🔹 The dilemma: Does every high-risk patient need intensification, especially without proven OS benefit?
Positive trial ≠ Treat everyone. Patient selection matters!
📖 NEJM Correspondence (2026)
DOI: 10.1056/NEJMc2611613
#PROTEUS #ProstateCancer #Oncology #MVOnco
@OncoAlert @OncoDaily @larvol
EV + pembrolizumab vs. EV + durvalumab.
How does the VOLGA trial impact treatment decisions in muscle-invasive bladder cancer?
Listen to the full debate, recorded live at #UromigosLive in Nashville 🎸
🎧 Spotify: bit.ly/4kkdcQc
🎧 Apply: apple.co/48Gvvbn

ALT Panel discussion at the "The Uromigos Live & Unplugged" event, Nashville '26. Three individuals are seated on stage, engaged in a debate. The backdrop displays the topic: "EV + Pembro vs. EV + Durvalumab: Which would you choose?" The setting includes stage lights and a guitar silhouette in the corner.
د.عبدالله علي الشرم retweeted
🧐 HER2-low advanced gastric cancer (Gastric Cancer, Samsung NGS cohort)
This is for gastric cancer specialists.
Will HER2-low ever be a thing in gastric cancer?
With upcoming ADCs, maybe yes 🤷♂️... So let's take a look at this:
👥 1,067 patients: HER2-negative 75.4%, HER2-low 14.7%, HER2-positive 9.8%
🎯 HER2-low had the highest PD-L1 CPS≥5 rate (60.1%) and MSI-H (7.0%)
🧬 Enriched for DDR alterations (BARD1, SLX4) and PI3K/AKT changes
➖ Chemo + IO cohort OS 20.0 vs 16.9 mo, HR 0.83, p=0.157, not significant
Two Korean cohorts now call HER2-low gastric cancer a distinct subgroup, and they do not agree on what makes it distinct:
- In May, a 2,007-patient Yonsei series tied HER2-low to an angiogenesis signature and worse survival;
- this week's 1,067-patient Samsung NGS cohort ties it to DDR alterations, PI3K/AKT, and the highest PD-L1 and MSI-H rates.
Even the prevalence moves: 14.7% here, 26.1% at Yonsei.
Well... before HER2-low becomes an ADC selection criterion in gastric cancer the way it is in breast, it would be nice if IHC 1+ meant the same thing across pathologists.
#GastricCancer #HER2 #GIOnc #PrecisionMedicine
pubmed.ncbi.nlm.nih.gov/4302…
esmoopen.com/article/S2059-7…
د.عبدالله علي الشرم retweeted
RESECTABLE GASTRIC CANCER: 25 YEARS OF TREATMENT EVOLUTION (2001–2026)
From surgery alone to chemotherapy, chemoimmunotherapy and biomarker-guided treatment.
A two-part journey through the landmark trials that transformed curative-intent treatment.
PART 1 | HOW CHEMOTHERAPY BECAME THE STANDARD
- INT-0116, MAGIC, ACTS-GC, CLASSIC: Established postoperative and perioperative systemic treatment.
- FLOT4: Improved median OS (50 vs 35 months; HR 0.77).
- RESOLVE & PRODIGY: Strengthened D2-based adjuvant and neoadjuvant strategies.
PART 2 | BEYOND FLOT
- MATTERHORN: Durvalumab + FLOT improved EFS (HR 0.71) and OS (HR 0.78).
- ASTRUM-006: Promising EFS benefit with serplulimab + SOX.
- KEYNOTE-585: No statistically significant OS benefit.
- ARTIST 2, CRITICS, TOPGEAR: Routine radiotherapy intensification has not consistently improved survival.
- ESOPEC: FLOT outperformed CROSS in oesophageal adenocarcinoma.
- NEONIPIGA: Promising chemotherapy-free immunotherapy in dMMR/MSI-H disease.
THE BIG PICTURE: Surgery remains fundamental. Systemic therapy has transformed outcomes. The future is increasingly biomarker-guided.
📚 References: NEJM — INT-0116, MAGIC, MATTERHORN, ESOPEC | Lancet — CLASSIC, FLOT4 | Lancet Oncol — RESOLVE | JCO — ACTS-GC, PRODIGY, KEYNOTE-585, NEONIPIGA | ASTRUM-006 (2026).
#GastricCancer #StomachCancer #GIOncology #MedicalOncology #FLOT #Immunotherapy #CancerResearch #OncologyTrials #PrecisionOncology
@OncoDaily @OncoAlert @larvol
د.عبدالله علي الشرم retweeted
🚨 dMMR ≠ Lynch syndrome!
A crucial distinction every oncologist should know.
A new Lancet review highlights the diagnostic pathway:
🔬 MLH1/PMS2 loss? Check BRAF V600E and/or MLH1 methylation.
🧬 MSH2/MSH6 or isolated MSH6/PMS2 loss? Consider germline testing.
🔍 Germline negative? Look for double-somatic MMR alterations.
💡 Key message: Tumour MMR deficiency is a starting point, not a hereditary cancer diagnosis.
📊 Save this diagnostic algorithm!
@oncoalert @esmo_open @myesmo @asco
#LynchSyndrome #PrecisionOncology
Full paper link in comment below ⬇️.
د.عبدالله علي الشرم retweeted
PROTEUS: A positive trial, but does every high-risk prostate cancer patient need intensification? 🤔
An interesting NEJM correspondence challenges how we interpret the PROTEUS results.
🔹 The benefit: MFS improved (HR 0.80; P = 0.02), with a 4.7% absolute gain at 5 years.
🔹 The controversy: PSMA PET-inclusive MFS was statistically significant, but conventional-imaging MFS was not (HR 0.84).
🔹 The authors' defense: Both analyses favour treatment; fewer conventional-imaging events limit statistical power.
🔹 Beyond statistics: Endpoint modification, unequal PSMA PET use, heterogeneous risk, positive surgical margins and treatment burden raise important questions.
My takeaway: PROTEUS is positive, but OS benefit remains unproven. Patient selection, absolute benefit and toxicity matter.
A positive trial ≠ Treat every patient.
📖 NEJM Correspondence, 12 Nov 2026
DOI: 10.1056/NEJMc2611613
#PROTEUS #ProstateCancer #Oncology #ClinicalTrials #MVOnco
@OncoAlert @OncoDaily @larvol
د.عبدالله علي الشرم retweeted
BLADDER CANCER TREATMENT JUST TOOK AN IMPORTANT STEP FORWARD!
The FDA has approved a new perioperative treatment strategy combining durvalumab and enfortumab vedotin for patients with muscle invasive bladder cancer who cannot receive or decline cisplatin based chemotherapy
The approval is based on the Phase 3 VOLGA trial involving 695 patients
The treatment strategy is particularly interesting
Three cycles of enfortumab vedotin plus durvalumab before surgery followed by radical cystectomy and additional durvalumab afterward
The goal is to attack the cancer before surgery and reduce the risk of recurrence after surgery
The results are clinically meaningful
At 24 months
Event free survival
63.5% with durvalumab plus enfortumab vedotin
45.1% with surgery alone
Overall survival
78.4% versus 69.4%
The combination reduced the relative risk of death by 42% and the risk of an event or death by 49%
Pathological complete response was also impressive
45.1% with the combination
9.6% with surgery alone
But there is an important clinical consideration
Grade 3 or higher adverse events occurred in 71.1% of patients receiving the combination compared with 50.2% in the control group
This is not a treatment without toxicity
For patients who cannot receive cisplatin based chemotherapy this represents an important new option
Several questions deserve attention
Could this approach change the standard of care for cisplatin ineligible patients with muscle invasive bladder cancer?
Can circulating tumor DNA help identify patients who need additional postoperative treatment?
Can we eventually identify patients who may safely avoid radical cystectomy after achieving a complete response?
Could molecular profiling help determine who benefits most from this combination?
The broader lesson is important
Cancer treatment is increasingly moving beyond the traditional sequence of chemotherapy followed by surgery
We are entering an era in which targeted therapy and immunotherapy can be integrated before and after surgery with curative intent
The challenge now is to maximize survival while reducing toxicity and preserving quality of life
Are we approaching a new era of bladder preservation and personalized perioperative oncology?
#BladderCancer #Immunotherapy #Oncology #CancerResearch #PrecisionMedicine
د.عبدالله علي الشرم retweeted
Exciting new directions in 1L mRCC! 🧬
Particularly interesting to see PD-1×VEGF bispecifics entering the RCC landscape.
However, following the recent FDA setback for ivonescimab in NSCLC, an important reminder: promising early activity and PFS signals are not enough—we need durable survival benefit and favorable tolerability.
After several disappointing triplet trials, perhaps the future is not simply adding more drugs, but better patient selection and smarter combinations.
And most importantly: how can we identify patients who achieve durable IO-driven remission and potentially avoid chronic TKI toxicity?
Great discussion at #UromigosLive! 👏
@OncoAlert @weoncologists @urotoday @Uromigos
@OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
Beyond the usual triplets, 3 new ideas in 1L mRCC #kidneycancer to watch #UromigosLive:🔹Ivonescimab (PD-1/VEGF bispecific) ph1🔹PEAK-20 ph3:casdatifan added to ipi/nivo🔹PDIGREE Ph3: ORR-adapted ipi/nivo, then nivo ± cabo👉@Uromigos @OncoAlert @brian_rini @tompowles1 @montypal
د.عبدالله علي الشرم retweeted
Pembrolizumab plus FLOT as neoadjuvant and adjuvant therapy in locally advanced gastric and gastroesophageal junction cancer: analysis of the FLOT cohort from the phase 3 KEYNOTE-585 study
esmoopen.com/article/S2059-7…
There are now 2 (EVP and EVD) FDA approved regimens available in MIBC . The panel @tompowles1 @shilpaonc @MichvdHeijden @kalasri3 @DrRosenbergMSK @MattGalsky @PGrivasMDPhD @JoshMeeks Anna Wilkins
Rough conclusion from #UromigosLive :
👉Both these regimens are better than any other option. Both trials are robust and very positive. Both are a reasonable approach. EV/D 1st ask questions later @MichvdHeijden
👉EVP gives you the flexibility to give the adjuvant period if you want, and some may need it, especially the higher TNM stage. Biomarkers don’t help @DrRosenbergMSK
👉It’s not clear who needs the adjuvant period, but 9 cycles is not for everyone. Most in the trials didn’t get to 9 cycles @shilpaonc
👉EVD does not have the adjuvant ADC period and will be attractive for some patients and doctors.
👉Stick to the protocol and don’t let ctDNA or pCR or TMT take you off course too much @MosheOrnsteinMD
👉Bladder sparing are already attractive @kalasri3 but let’s wait for the trial results @MattGalsky
👉’Pick one and use it well’ maybe more imporant than the deliberation over the optimal regimen as it’s true that only half the pateint finish the IO therapy. @tompowles1
د.عبدالله علي الشرم retweeted
Beyond the usual triplets, 3 new ideas in 1L mRCC #kidneycancer to watch #UromigosLive:🔹Ivonescimab (PD-1/VEGF bispecific) ph1🔹PEAK-20 ph3:casdatifan added to ipi/nivo🔹PDIGREE Ph3: ORR-adapted ipi/nivo, then nivo ± cabo👉@Uromigos @OncoAlert @brian_rini @tompowles1 @montypal
د.عبدالله علي الشرم retweeted
🧬 One size does NOT fit all in muscle-invasive bladder cancer!
With EV+pembrolizumab (EVP), EV+durvalumab and chemoimmunotherapy reshaping perioperative MIBC treatment, the next challenge is identifying which patient benefits from which regimen.
Urothelial cancer is biologically heterogeneous!
Low/absent membranous NECTIN4 and divergent histomorphology, particularly squamous differentiation, may identify tumors at risk of limited durable benefit from EV-based therapy.
Intriguingly, emerging #ESMO26 subgroup data suggest that these basal/squamous differentiated tumors may respond well to gemcitabine/cisplatin + durvalumab (pCR ~50%).
⚠️ These are hypothesis-generating signals, not yet validated treatment-selection biomarkers.
Excited that our prospective, multicenter EVOKE-2 registry, together with @Markuseckstein3 and colleagues from GUARDIANS, has already launched to investigate NECTIN4 expression, histomorphology and clinical outcomes for perioperative EVP/D!
The goal: match the right biology to the right treatment. 🎯
#BladderCancer #MIBC #GUOncology
@OncoAlert @weoncologists @urotoday @Uromigos
@OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
د.عبدالله علي الشرم retweeted
Plethora of options in mAMPS:
Chemo triplet still strong role
PARPi strongest for BRCA. Biallelic loss of non-HRR (ATM) can be impt
Pluvicto, consider for high mean PSMA
PTEN need scans q3m if low PSA w/ Capi (esp for loss>99) or chemo
& AEs for all
#UromigosLIVE @OncoAlert
د.عبدالله علي الشرم retweeted
Front-line chemo-hormonal therapy for APMS prostate cancer is not one size fits all - for patients with high-risk genomic features (PTEN loss etc...) it's a viable option.
Nice discussion live from @brian_rini @AttardLab @TDorffOnc @neerajaiims and Evan Yu
#uromigos @UroVoices
د.عبدالله علي الشرم retweeted
Important point from the panel: None of the 3 belzutifan trials in adjuvant or advanced RCC have demonstrated a statistically significant OS benefit.
Shared decision-making is especially critical in adjuvant ccRCC. Patient-reported long-term toxicity data should inform these discussions.
STRIKE (Alliance A032201) remains open for enrollment. @BradMcG04
#UromigosLive #uromigos
د.عبدالله علي الشرم retweeted
Do you want to know more about the management of hepato-pancreato-biliary (including neuroendocrine) malignancies?
Maybe learn from experts like @AGangiMD on the surgical management of pancreatic NETs but she provided an excellent overview from which the following slides were lifted...?
Then mark your 2027 calendar and join us for the 2027 Hepato-Pancreatico-Biliary Cancer Symposium on Nov 5-6, 2027.
Ideal content for anyone taking care of such patients, especially trainees in surgery and oncology. Cutting edge and practical.
ce.mayo.edu/gastroenterology…
@MayoCancerCare @GIcancerDoc @MiteshBorad
د.عبدالله علي الشرم retweeted
DYNAMIC-III trial – ctDNA-guided Adjuvant therapy in stage III colon cancer
Who need more intensive chemotherapy and who can safely receive less chemotherapy after curative surgery?
Are we there yet ??
Lets Explore this wonderful trial
د.عبدالله علي الشرم retweeted
🚨 PROTEUS: periop apalutamide + ADT in high-risk localized #ProstateCancer (N=2109). Dual primary endpoints: pCR/MRD and MFS improved. Neoadjuvant ADT alone never moved clinical outcomes. #UromigosLive @Uromigos @OncoAlert @NehaVapiwala @dr_coops @AttardLab @brian_rini
د.عبدالله علي الشرم retweeted
ADT + ARPI in (very) high-risk non-metastatic #ProstateCancer: three trials, three different populations.
MFS HR in all patients👉
STAMPEDE (abiraterone) 0.53
ENZARAD (enzalutamide) 0.88
DASL-HiCaP (darolutamide) 0.42
👉In cN1: 0.49 / 0.43 / 0.39. Case-mix matters. #UromigosLive @Uromigos @NehaVapiwala @dr_coops @AttardLab
🚨 PROTEUS: periop apalutamide + ADT in high-risk localized #ProstateCancer (N=2109). Dual primary endpoints: pCR/MRD and MFS improved. Neoadjuvant ADT alone never moved clinical outcomes. #UromigosLive @Uromigos @OncoAlert @NehaVapiwala @dr_coops @AttardLab @brian_rini




























































